Drug Profile
Research programme: epithelial sodium channel antagonists - Parion Sciences
Alternative Names: P 1055; VX 551Latest Information Update: 14 Jul 2023
Price :
$50
*
At a glance
- Originator Parion Sciences
- Class Antifibrotics; Mucolytics; Small molecules
- Mechanism of Action Epithelial sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cystic fibrosis; Primary ciliary dyskinesia
- No development reported Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis
Most Recent Events
- 14 Jul 2023 Preclinical development is ongoing for Cystic fibrosis in USA (Inhalation) (Parion Sciences pipeline, July 2023)
- 13 Jul 2023 Preclinical trials in Primary ciliary dyskinesia in USA (Inhalation) prior to July 2023 (Parion Sciences pipeline, July 2023)
- 28 Jul 2021 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA